The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Patents, Royalties, Other Intellectual Property - Royalty with Anasys Instruments
A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation.
 
Thatcher Ross Heumann
Honoraria - Total Health
Consulting or Advisory Role - AstraZeneca; Eisai; Elevar Therapeutics; Primum
Travel, Accommodations, Expenses - Eisai
 
Shannon Stockton
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck
 
Michael Cecchini
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Agenus; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; DAVA Pharmaceuticals; Elevation Oncology; Incendia Therapeutics; Loxo/Lilly; Macrogenics; Regeneron; Seagen; Taiho Oncology
 
Raid Aljumaily
Research Funding - Abbvie (Inst); Alliance Foundation Trials (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxalta (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Huntsman Cancer Institute (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Syneos Health (Inst); Tesaro (Inst)
 
Cathy Shyr
No Relationships to Disclose
 
Jennifer Whisenant
No Relationships to Disclose
 
Jason S. Starr
Consulting or Advisory Role - Cancer Expert Now; Helsinn Therapeutics; Ipsen; Natera; Pfizer; Taiho Oncology; Tempus; Tersera
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Camurus (Inst); Incyte (Inst); Leap Therapeutics (Inst); Macrogenics (Inst); Merus (Inst); Molecular Templates (Inst); Rafael Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Camurus
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis
Speakers' Bureau - Astellas Pharma; Exelixis; ipsen; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Joaquina Celebre Baranda
Stock and Other Ownership Interests - Aprea Therapeutics; Merus NV; Moderna Therapeutics; Zymeworks
Research Funding - Astellas Pharma (Inst); Chungchun Intellicrown (Inst); Exelixis (Inst); IMPAC Medical Systems (Inst); Merck (Inst); Poseida (Inst); Sanofi (Inst); Synermore (Inst); Xencor (Inst)
 
Nikolaos Trikalinos
Research Funding - Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Merck (Inst); Novartis (Inst); Nykode Therapeutics (Inst)
 
S. Percy Ivy
No Relationships to Disclose
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Actuate Therapeutics; Agenus; Amgen; AstraZeneca; Atreca; BAKX Therapeutics; Boehringer Ingelheim; Compass Therapeutics; Cullinan Oncology; DAAN Biotherapeutics; EMD Serono; GlaxoSmithKline; I-Mab; ImCheck therapeutics; IQvia; Kineta; Kyowa Kirin International; Mekanistic Therapeutics; Mersana; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Quanta Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Scenic Biotech; Schrodinger; Seagen; Sotio; ST Cube; Stemline Therapeutics; Takeda; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Satya Das
Employment - AstraZeneca; Cullgen
Consulting or Advisory Role - Cancer Expert Now
 
Steven Gore
No Relationships to Disclose
 
Jan Hendrik Beumer
Employment - Voisin Consulting (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Research Funding - TriSalus Life Sciences (Inst)
Patents, Royalties, Other Intellectual Property - Sulphoraphane for melanoma chemoprevention (Inst)
Expert Testimony - Astellas Pharma; AstraZeneca/Merck
(OPTIONAL) Uncompensated Relationships - Applied Isotope Technologies; Qrono
 
Jordan Berlin
Consulting or Advisory Role - Bayer Health; Bexion; BioSapien; Bristol-Myers Squibb/Celgene; insmed; ipsen; Mekanistic Therapeutics; Merck; Merck KGaA; Merus; Mirati Therapeutics; Oxford BioTherapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incendia Pharmaceuticals AB (Inst); Incyte (Inst); Lilly (Inst); ribosciences (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst); Volastra Therapeutics (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure